This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: "2,5-Dimethoxy-4-trifluoromethylamphetamine" – news · newspapers · books · scholar · JSTOR (April 2015)
Clinical data
Other names2,5-Dimethoxy-4-trifluoromethylamphetamine
Legal status
Legal status
  • (RS)-1-[2,5-Dimethoxy-4-(trifluoromethyl)phenyl]propan-2-amine
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass263.260 g·mol−1
3D model (JSmol)
  • FC(F)(F)c1cc(OC)c(cc1OC)CC(N)C
  • InChI=1S/C12H16F3NO2/c1-7(16)4-8-5-11(18-3)9(12(13,14)15)6-10(8)17-2/h5-7H,4,16H2,1-3H3 checkY
 ☒NcheckY (what is this?)  (verify)

2,5-Dimethoxy-4-trifluoromethylamphetamine (DOTFM) is a psychedelic drug of the phenethylamine and amphetamine chemical classes. It was first synthesized in 1994 by a team at Purdue University led by David E. Nichols.[1] DOTFM is the alpha-methylated analogue of 2C-TFM, and is around twice as potent in animal studies. It acts as an agonist at the 5HT2A and 5HT2C receptors.[1] In drug-substitution experiments in rats, DOTFM fully substituted for LSD and was slightly more potent than DOI.[1]

See also


  1. ^ a b c Nichols DE, Frescas S, Marona-Lewicka D, Huang X, Roth BL, Gudelsky GA, Nash JF (1994). "1-(2,5-Dimethoxy-4-(trifluoromethyl)phenyl)-2-aminopropane: a potent serotonin 5-HT2A/2C agonist". Journal of Medicinal Chemistry. 37 (25): 4346–4351. doi:10.1021/jm00051a011. PMID 7996545.